Literature DB >> 6482171

Parathyroid and bone response of the diabetic patient to uremia.

F Vincenti, S B Arnaud, R Recker, H Genant, W J Amend, N J Feduska, O Salvatierra.   

Abstract

Biochemical and radiologic indices of bone disease were assessed in 26 insulin-dependent diabetic patients and 28 nondiabetic patients with endstage kidney disease. The two groups were comparable in age, sex, duration of renal failure, and length of time on dialysis. Diabetic patients showed significantly lower serum calcium and immunoreactive parathyroid hormone (iPTH) levels than nondiabetic patients. iPTH was not related to total serum calcium, but was positively correlated with serum phosphorous (r = 0.37, P less than 0.05 and r = 0.54, P less than 0.005, in nondiabetic and diabetic patients, respectively). iPTH correlated with alkaline phosphatase (r = 0.59, P less than 0.0009) and calcitonin (r = 0.51, P less than 0.05) only in nondiabetic patients. Osteitis fibrosa was noted radiologically in 30% of nondiabetic patients and in none of the diabetic patients (P less than 0.03). Bone morphology in eight diabetic patients who underwent iliac bone biopsy was characterized by reduced trabecular and osteoid bone volume, no woven bone, and marked reduction in indices of bone formation and resorption. The small amount of bone and lack of osteomalacia are a unique feature of the diabetic patient with chronic renal disease. The long-term sequelae of low bone turnover and reduced circulating iPTH may present a special problem to the long term diabetic survivor on the current therapies of uremia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6482171     DOI: 10.1038/ki.1984.73

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

1.  Associations between serum leptin level and bone turnover in kidney transplant recipients.

Authors:  Csaba P Kovesdy; Miklos Z Molnar; Maria E Czira; Anna Rudas; Akos Ujszaszi; Laszlo Rosivall; Miklos Szathmari; Adrian Covic; Andras Keszei; Gabriella Beko; Peter Lakatos; Janos Kosa; Istvan Mucsi
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 8.237

2.  Osteodystrophy of diabetics in chronic dialysis: a histomorphometric study.

Authors:  J Aubia; S Serrano; L Mariñoso; L Hojman; A Diez; J Lloveras; J Masramon
Journal:  Calcif Tissue Int       Date:  1988-05       Impact factor: 4.333

Review 3.  Bone and mineral disorders in pre-dialysis CKD.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

4.  Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease.

Authors:  Patricia Wahl; Huiliang Xie; Julia Scialla; Cheryl A M Anderson; Keith Bellovich; Carolyn Brecklin; Jing Chen; Harold Feldman; Orlando M Gutierrez; Jim Lash; Mary B Leonard; Lavinia Negrea; Sylvia E Rosas; Amanda Hyre Anderson; Raymond R Townsend; Myles Wolf; Tamara Isakova
Journal:  Diabetes Care       Date:  2012-03-23       Impact factor: 19.112

5.  Adynamic bone disease-bone and beyond.

Authors:  Vincent M Brandenburg; Jürgen Floege
Journal:  NDT Plus       Date:  2008-06

6.  Rapid decrease of intact parathyroid hormone could be a predictor of better response to cinacalcet in hemodialysis patients.

Authors:  Jwa-Kyung Kim; Young Joo Kwon; Soo Wan Kim; Yeong-Hoon Kim; Cheol Whee Park; Kyu Bok Choi; Seung Duk Hwang; Kyu Hun Choi
Journal:  Yonsei Med J       Date:  2013-03-01       Impact factor: 2.759

Review 7.  Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis.

Authors:  Jianzhen Ye; Guangrui Deng; Feng Gao
Journal:  Drug Des Devel Ther       Date:  2018-04-19       Impact factor: 4.162

Review 8.  Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony.

Authors:  Stanley M H Yeung; Stephan J L Bakker; Gozewijn D Laverman; Martin H De Borst
Journal:  Curr Diab Rep       Date:  2020-08-28       Impact factor: 4.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.